This site is intended for healthcare professionals

Ardelyx announces publication of 52-week phase III PHREEDOM trial

Read time: 1 mins
Last updated:10th Sep 2021
Published:10th Sep 2021
Ardelyx, Inc. announced the publication of the company's long term 52-week Phase III PHREEDOM trial in the American Society of Nephrology journal, Kidney360.
Condition: Hyperphosphataemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest